Monitoring anti-TFPI in severe hemophilia patients on Marstacimab
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at how a medicine called Marstacimab affects your body's natural anti-clotting protein (TFPI) in people with severe hemophilia A or B who are already taking it. It involves blood tests to see how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and 18 years or older.
- You have severe hemophilia A (factor VIII level less than 1%) or severe hemophilia B (factor IX level less than 2%).
- You are currently getting Marstacimab injections to prevent bleeding.
- You are willing to stop your regular factor VIII or IX shots for a few days before the study (2 days for short-acting factor VIII, 4 days for long-acting factor VIII, or 10 days for long-acting factor IX).
- You are willing to give 4 extra blood samples for research.
- You do not have any other bleeding disorder besides hemophilia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study follows people with hemophilia A or B who are taking marstacimab as their regular preventive treatment. It aims to understand how the medicine works in real life and how patients feel during treatment.
This study looks at a medicine called marstacimab for people with hemophilia A or B. If you are already taking marstacimab or have a prescription for it, this study may help us learn more about how well it works.
This study looks at how prophylactic treatment for hemophilia affects your daily life, sleep, and feelings about your health. It compares different types of clotting factor concentrates to see if one is easier to manage than the other.
This study tests if switching from emicizumab to a new medicine called marstacimab is safe and effective for people with severe hemophilia A. You must have been on emicizumab for at least 6 months and not have a history of blood clots or heart disease.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
This Phase 3 study looks at how well and how safely marstacimab works over a longer follow-up period. You may join if you already finished a related parent study for hemophilia, and you can keep up with frequent visits and lab tests.
Hear when a new Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.